David Snow, MD
Psychiatry · Maryville, TNNPI 1821096041
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $504,441 of the $605,365 with a category attached, or 83.3%. 33 manufacturers reported payments, led by AbbVie at 34.0% of the total. Reporting peaked in 2023 at $134,798 and has fallen 66.3% since, to $45,477 in 2025. Among psychiatry clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,551 payments — averaging $390.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$206K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$205K
- Axsome Therapeutics, Inc.$51K
- Supernus Pharmaceuticals, Inc.$49K
- Otsuka America Pharmaceutical, Inc.$44K
- Sunovion Pharmaceuticals Inc.$29K
- plus $21K from 27 others
What the payments were for
- Consulting fees$43,2387%
- Speaking & faculty fees$504,44183%
- Travel & lodging$36,1526%
- Food & beverage$21,5214%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$605,365 in reported general payments places this provider in the 95th percentile of 503 psychiatry providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 13 | $98,769 |
| NuedextaDextromethorphan Hbr/Quinidine | 15 | $46,068 |
| TrintellixVortioxetine Hydrobromide | 23 | $19,464 |
| VyvanseLisdexamfetamine Dimesylate | 25 | $13,118 |
| Bupropion XlBupropion Hcl | 229 | $10,759 |
| Vilazodone Hcl | 53 | $8,620 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 204 | $7,218 |
| Lisdexamfetamine Dimesylate | 18 | $4,524 |
| Quetiapine Fumarate | 202 | $4,347 |
| Aripiprazole | 106 | $3,302 |
| Lamotrigine | 175 | $3,204 |
| Clonazepam | 370 | $3,016 |
| Alprazolam | 590 | $2,932 |
| Oxcarbazepine | 35 | $2,527 |
| Gabapentin | 165 | $2,456 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,320 | $98,76913 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $474 | $46,06815 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $448 | $32,58248 claims |
| Almatica Pharma LLCSertraline Hcl | $52 | $1,142156 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 503 psychiatry providers in Tennessee.
Other psychiatry in Maryville
- Sharon ChastainMaryville$9K
- Rakesh AminNashville$3M
- Brian BonfardinJohnson City$2.6M
- John FenleyJohnson City$1.4M
- Karthi NamasivayamKnoxville$225K
- Robert JamiesonNashville$141K
- George BrownJohnson City$91K
- Sricharan MoturiFranklin$82K
- Michelle CochranNashville$74K
- Daniel BoydMemphis$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.